Illumina releases SpliceAI2 to help advance rare disease research
In a rare disease research dataset, SpliceAI2 identified 17% more disease-relevant variants compared to other splicing models Illumina's genomic AI models now collectively enable researchers to identify 2x as many variants with predicted biological impact SAN DIEGO, Oct. 8, 2026...
Covered in this story
Call it yourself
No calls on $ILMN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Illumina →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.